,1 5-Fluorouracil (5-FU) is the first rationally designed antimetabolite, which achieves its therapeutic efficacy through inhibition of the enzyme thymidylate synthase (TS), which is essential for the synthesis and repair of DNA. However, prolonged exposure to 5-FU induces TS overexpression, which leads to 5-FU resistance in cancer cells. Several studies have identified curcumin as a potent chemosensitizer against chemoresistance induced by various chemotherapeutic drugs. In this study, we report for the first time, with mechanism-based evidences, that curcumin can effectively chemosensitize breast cancer cells to 5-FU, thereby reducing the toxicity and drug resistance. We found that 10 lM 5-FU and 10 lM curcumin induces a synergistic cytotoxic effect in different breast cancer cells, independent of their receptor status, through the enhancement of apoptosis. Curcumin was found to sensitize the breast cancer cells to 5-FU through TS-dependent downregulation of nuclear factor-jB (NF-jB), and this observation was confirmed by silencing TS and inactivating NF-jB, both of which reduced the chemosensitizing efficacy of curcumin. Silencing of TS suppressed 5-FU-induced NF-jB activation, whereas inactivation of NF-jB did not affect 5-FU-induced TS upregulation, confirming that TS is upstream of NF-jB and regulates the activation of NF-jB in 5-FU-induced signaling pathway. Although Akt/PI3kinase and mitogen-activated protein kinase pathways are activated by 5-FU and downregulated by curcumin, they do not have any role in regulating the synergism. As curcumin is a pharmacologically safe and cost-effective compound, its use in combination with 5-FU may improve the therapeutic index of 5-FU, if corroborated by in vivo studies and clinical trials.
Subject Category: Cancer
Eradication of breast cancer is currently a demanding arena owing to the challenges faced in developing an adequate drug for its treatment because of the heterogeneity in receptor status of breast cancer tissues. Drugs for breast cancer treatment are selected based on estrogen, progesterone and HER2/neu receptor status of the tissue. In the case of triplenegative breast cancer, which is devoid of ER/PR/HER2/neu receptors, the currently available chemotherapeutic regimens fail, demanding better treatment modalities that can act independent of the receptor status.
The major lacunae in conventional chemotherapy are their adverse side effects and the development of chemoresistance, which they induce by upregulating various survival signaling pathways and multidrug resistance genes. Any compound, which can downregulate these survival signals, can act as a chemosensitizer and can increase the efficacy of chemotherapy. Several phytochemicals have been reported to act as potent chemosensitizers in combination with conventional chemotherapeutic drugs 1, 2 and are preferred over synthetic chemicals because they have been proven to be pharmacologically safe. 3 The antimetabolite agent 5-fluorouracil (5-FU) is widely used in the treatment of many types of cancers including breast cancer. 4 It inhibits cancer cell growth and initiates apoptosis by targeting thymidylate synthase (TS), an enzyme crucial for the de novo synthesis of DNA, 5 and also by inducing DNA and RNA strand breaks by direct incorporation of fluorinated nucleotides. 6, 7 5-FU chemotherapy is hampered by side effects like leukopenia, diarrhea, anorexia and vomiting. 8 In vitro and in vivo studies have established a strong association between increased TS expression and development of 5-FU chemoresistance. 9, 10 Multiple clinical investigations have shown an improved response to 5-FU-based therapy in patients with low TS expression in the tumor tissues. 11 In addition to the well-established concept that TS is a target of fluoropyrimidine, it is also reported as an oncogene.
as PI3kinase/Akt, EGFR, and so on, further contributing to chemoresistance. Thus, downregulation of NF-kB by chemopreventives is an effective mechanism to tackle drug resistance. 14 The therapeutic efficacy of 5-FU is significantly increased when NF-kB nuclear translocation and activation is prevented. [15] [16] [17] Akt, which has a major function in cell survival and proliferation, has an important role in 5-FU chemoresistance. 18 Evidences indicate that Akt is frequently activated in breast cancer and makes breast cancer patients more prone to tumor relapse and metastasis. 19 Besides these survival pathways, ERK1/2 (p42/44), p38 and JNK -the three major mitogen-activated protein kinases (MAPKs) -have been widely implicated in the cancer chemoresistance owing to their constitutive and drug-induced activation. 20 Inhibition of ERK has been shown to enhance the activity of 5-FU. 18 Curcumin is an ideal chemopreventive agent owing to its diverse effects on multiple signaling pathways 21 and pharmacological safety. 22 It sensitizes cancer cells to chemotherapeutic agents by inhibiting antiapoptotic pathways. 2, 23 Several studies have shown that curcumin can sensitize cancer cells of various origin to 5-FU. [24] [25] [26] Although 5-FU is commonly used in breast cancer treatment, no study has been conducted on the effect of 5-FU and curcumin in breast cancer.
This study was carried out to find out whether curcumin can chemosensitize breast cancer cells to 5-FU, inducing a synergistic cytotoxicity to them, and to elucidate the signaling pathways regulating the synergism.
Results
A synergistic combination of 5-FU and curcumin induces enhanced cytotoxicity and apoptosis in breast cancer cells, while the normal immortalized breast cells are unaffected. 5-FU and curcumin were screened for their cytotoxicity, both individually and in combination, towards various breast cancer cell lines and the normal immortalized breast epithelial cell line MCF 10A by MTT assay (Figure 1a) . Among the various combinations studied, the combination of 10 mM 5-FU and 10 mM curcumin was found to induce a synergistic cytotoxic effect compared with that caused by either of the two compounds alone in breast cancer cells. The combination index (CI) value was o1 in all breast cancer cells for the combination, indicating synergism, whereas 41 in the normal immortalized breast epithelial cell line MCF 10A, indicating an antagonistic effect (Supplementary Table 1 ). As the synergism was almost similar among all the breast cancer cells studied, we selected MDA-MB-231, the triple-negative cell line for further studies, to ensure that the synergism is independent of the receptor status. Although 10 mM 5-FU and 10 mM curcumin induced 29% and 12% cytotoxicity, respectively, in MDA-MB-231 cells, a combination of these two induced 58% cytotoxicity, which is more than that induced by 25 mM 5-FU. This enhanced cytotoxicity is due to the synergistic effect of 5-FU and curcumin, as an additive effect of both these compounds should have induced only 41% cytotoxicity (Figure 1a) . The synergism was further confirmed in MDA-MB-231 cells by a more reliable [ 3 H]thymidine incorporation assay (Figure 1b ). These results indicate that curcumin and 5-FU, when used in combination, induce more than double the effect of 5-FU alone, whereas curcumin itself does not induce a significant cytotoxicity at this concentration. However, this combination was non-toxic to MCF 10A, indicating that the combination is biologically safe (Figure 1c ). FACS analysis indicated that while 5-FU alone induces an S-phase arrest, treatment of curcumin along with 5-FU pushed the cells to apoptotic death as indicated by the tremendous increase (from 6.8 to 43.1%) in the number of cells in the sub-G0 phase (Figure 1d ).
The enhancement of 5-FU-induced apoptosis by curcumin, as evidenced by Annexin V positivity, is through caspase-mediated cleavage of PARP, leading to DNA fragmentation. The results from Annexin V/PI staining were also in concordance with that of the MTT assay ( Figure 2a ) and clearly indicate that curcumin enhances externalization of phosphatidylserine. The combination induced a significant cleavage of procaspase-8 to its active fragments (p43/41) and procaspase-9 to its active fragments (p35/37) (Figures 2b and c) compared with cells treated with either of the two compounds alone. The combination also induced the cleavage of procaspase-3 to its active fragments (p17/19) and enhanced the cleavage of procaspase-7 to its active fragment (p20) (Figures 2d and e) . In addition, it induced enhanced cleavage of PARP, the downstream target of caspase-3 ( Figure 2f ). The synergistic effect was confirmed through the enhancement of apoptosis when the combination induced momentous increase in the internucleosomal cleavage of DNA, the biochemical hallmark of apoptosis, compared with that induced by 5-FU and curcumin alone (Figure 2g ).
5-FU induces time-dependent upregulation of TS, which is downregulated by curcumin and silencing of TS abrogates the synergism. The main mechanism of action of 5-FU is the inhibition of TS by fluorodeoxyuridine monophosphate, the active metabolite of 5-FU. 4 However, studies indicate that 5-FU treatment induces TS expression, which might bypass deoxythymidine monophosphate depletion, leading to chemoresistance. 9 This effect is due to the inhibition of the negative-feedback mechanism, where TS inhibits its translation by binding to its own mRNA. 27 Several studies have demonstrated strong association between increased TS expression and development of resistance to 5-FU. 4, 28 Reports indicate that the expression of this enzyme is significantly upregulated in various tumors including breast cancer. 9, 10 This is the first report demonstrating the ability of curcumin to downregulate the expression of TS in breast cancer cells. We checked whether 5-FU upregulates the expression of TS at a concentration of 10 mM inducing synergism. We also observed the downregulation of TS by 5-FU at 6 h, followed by a time-dependent upregulation up to 48 h (Figure 3a) . Curcumin pre-treatment could significantly downregulate 5-FU-induced upregulation of TS (Figure 3b ). This prompted us to check whether the downregulation of TS by curcumin in breast cancer cells has any regulatory role in the synergism.
Hence, we silenced TS expression by transiently transfecting the MDA-MB-231 cells with TS siRNA, which completely silenced the TS expression at 200 p moles (Figure 3c ) and the viability of these cells treated with the compounds was compared with the data obtained for cells transfected with control siRNA. It was very interesting to note that the silencing It is evident from the above studies that TS and NF-kB have significant roles in regulating the synergism, while Akt/ PI3kinase or MAPK pathways do not, although all these signaling pathways are upregulated by 5-FU and downregulated by curcumin.
NF-jB is downstream and Akt and MAPKs are upstream of TS in 5-FU-induced signaling events. Our next effort was to locate the exact position of Akt, MAPKs, NF-kB and TS in the 5-FU-induced signaling cascade. We checked whether there is any cross-talk between TS, NF-kB, Akt and MAPK pathways in the 5-FU-mediated signaling events. We inhibited NF-kB with SN50 ( TS signaling pathway (Figures 6d and e) . We noticed an upregulation of TS, both in the control as well as in 5FU-treated wells in IkBa DM-transfected cells. Probably the cell is trying to upregulate TS through the MAPK pathway when NF-kB is inactivated. We observed a similar pattern of upregulation of the basal expressions of all the IAPs and cyclin D1 in IkBa DM cells as well as Akt DN cells compared with control, in another study too. 29 Supporting this Curcumin sensitizes the breast cancer cell lines SK-BR-3 and MCF7 also, to 5-FU, through the downregulation of TS and NF-jB. We checked whether the synergism exists in other breast cancer cells with different receptor status. Interestingly, 10 mM 5-FU induced drastic upregulation of TS in both SK-BR-3 and MCF7 cells, which is almost completely downregulated by curcumin (Figure 7a ). We also observed that NF-kB is activated in both the cell lines by 5-FU (Figure 7b ) and found that 10 mM curcumin inhibits it almost completely (Figure 7c ). We also silenced TS and shutdown NF-kB and compared the synergism of 5-FU and curcumin in these cells with that of respective controls. As observed in MDA-MB-231, silencing of TS and inactivation of NF-kB inhibited the synergism almost completely (Figure 7d ), establishing that TS and NF-kB play critical roles in regulating the chemotherapeutic effect of 5-FU in all breast cancer cells, independent of their receptor status.
Hence, our study indicates that curcumin can act as a chemosensitizer in 5-FU chemotherapy against breast cancer, independent of the receptor status. This is a very important finding, as the entire chemotherapeutic regimen currently available select the treatment mode considering the receptor status of the breast tissue, and frequent relapse of cancer is reported in patients with triple-negative receptor status. Therefore, our finding will be beneficial to the field of breast cancer chemotherapy, if validated through in vivo studies.
Discussion
The development of drug resistance and dose-limiting cytotoxicity greatly impede the use of 5-FU, which will form a covalent ternary complex with 5, 10-methylenetetrahydrofolate and TS, resulting in the inhibition of DNA synthesis. 30 The expression of TS, which is an important therapeutic target of 5-FU, has been found to increase after prolonged exposure to 5-FU, leading to the maintenance of free enzyme in excess than that bound to 5-FU, 10, 31 which has been reported to be the reason for the chemoresistance of 5-FU. 32, 33 The overexpression of TS not only reflects drug resistance to fluoropyrimidine but also indicates the biological aggressiveness of cancer cells. The cytotoxicity of 5-FU was significantly increased when TS was downregulated as a result of the reduced amount of its protein target. 34 Several studies have been conducted based on the concept that development of a new therapeutic strategy that reduces TS expression would be clinically important. 5-FU, in combination with 3n-butyrate, was shown to have a synergistic effect in colorectal cancer xenografts through the enhanced reduction of TS and prevention of thymidine salvage in DNA synthesis. 35 Inhibitors of histone deacetylase and mammalian target of rapamycin have been shown to enhance the antitumor activity of 5-FU in various cancer cells, through downregulation of TS. 36, 37 Moreover, the antisense downregulation of TS and gefitinibmediated downregulation of TS enhance the efficacy of 5-FU. 38, 39 Over and above these preclinical findings, several clinical studies showed consistent inverse relation between TS expression and 5-FU sensitivity. 40, 41 Consistent with these findings, we found a clear negative correlation between 5-FU cytotoxicity and TS expression in breast cancer cells, as evidenced by enhanced 5-FU cytotoxicity in response to the silencing of TS. Curcumin, a well-documented chemosensitizer, could clearly downregulate both basal and induced TS expression in breast cancer cells, thereby enhancing 5-FUinduced cytotoxicity in these cells, suggesting for the first time that TS downregulation by curcumin could be used as a major strategy in breast cancer treatment in combination with 5-FU.
Another major signaling pathway responsible for chemoresistance induced by various chemotherapeutics including 5-FU is NF-kB. Several studies have shown that downregulation of NF-kB by various means could enhance therapeutic efficacy of 5-FU. 15, 17 The ability of curcumin to downregulate constitutive and inducible NF-kB, thereby enhancing the activity of various chemotherapeutics, has been well documented. The in vitro and in vivo studies from our laboratory have shown that the antitumor effects of paclitaxel could be enhanced by curcumin in cervical cancer cells through the downregulation of paclitaxel-induced activation of NF-kB, Akt and Bcl-2. 2, 23, 29 In this study, we observed that curcumin could drastically downregulate 5-FU-induced NF-kB activation in all the breast cancer cells studied.
In addition to these pathways, Akt and MAPK pathways are also reported to be involved in 5-FU chemoresistance. 15, 18 However, our study indicates that these two pathways do not have any important role as far as the regulation of synergism is concerned, even though both these pathways are upregulated by 5-FU and downregulated by curcumin. Although reports have suggested that the activation of Akt and MAPK can activate NF-kB, 29 in this study we found that inhibition of both these pathways did not have an effect on NF-kB (Figures 6k  and l) . As the inhibitors of Akt or MAPKs could not completely inhibit 5-FU-induced upregulation of TS (Figures 6f and g ), it clearly indicates that 5-FU can still operate through TSdependent NF-kB pathway and regulate the synergism.
Cross-talk between TS and NF-kB pathways in 5-FU therapy has not been reported. However, high NF-kB expression and nuclear activity has been observed in several TS inhibitor-resistant cell lines. 42 It has also been shown that the downregulation of 5-FU-induced NF-kB and TS could enhance the efficacy of 5-FU chemotherapy. 43 However, no study has yet reported the interdependence of TS and NF-kB. In this study, we found that silencing of TS considerably inhibits both constitutive and 5-FU-induced NF-kB expression in the breast cancer cell line MDA-MB-231. We also observed that 5-FU upregulates TS and NF-kB, and curcumin downregulates both of them. The inhibition of TS as well as NF-kB considerably restrains the synergism of 5-FU and curcumin in all the breast cancer cells studied, independent of their receptor status. The signaling events regulating the synergism of 5-FU and curcumin are depicted in Figure 8 . Thus, this study opens a new strategy for enhancing the efficacy of 5-FU chemotherapy. The physiologically achievable concentration of 5-FU is 0.077-15.4 mM. 44 As our study indicates that the combined use of curcumin with 10 mM 5-FU can increase the cytotoxic effect of 5-FU to more than double, it will significantly enhance the efficacy of 5-FU chemotherapy without inducing any side effects. Curcumin is a pharmacologically safe compound and could clearly downregulate NFkB, both directly and also via TS, thereby circumventing 5-FU resistance. The physiologically achievable concentration of curcumin when used orally is around 2 mM. 45 However, recent studies including those from our lab indicate that liposomal as well as nanoformulations of curcumin are more water soluble 46, 47 and bioavailable, 48, 49 facilitating the intravenous administration of curcumin, rendering it amenable to systemic dosing. Moreover, several studies including that of ours indicate that bioavailable levels of curcumin are enough for producing synergistic cytotoxic effect with chemotherapeutics in vivo.
1,2 A recent review from our lab has given a detailed account of various modifications of curcumin to improve its bioavailability and solubility in aqueous medium. 3 Other flavonoids like apigenin 50 and tangeretin 51 have also been shown to enhance the therapeutic effectiveness of 5-FU in breast cancer cells.
In conclusion, this study provides an important mechanismbased knowledge with potential utility in overcoming chemoresistance induced by 5-FU, thereby offering survival benefit to breast cancer patients. However, before proceeding for clinical trials, the proposed mechanism needs to be validated by in vivo studies, and our lab is currently carrying out experiments in this direction.
Materials and Methods
Cell lines. The breast cancer cell lines MCF7, MDA-MB-231, SK-BR-3 and T47D were purchased from National Center for Cell Sciences (Pune, India) and the normal immortalized breast epithelial cell line MCF10A (ATCC, Manassas, VA, USA) was a gift from Dr. S Sreeja (Rajiv Gandhi Center for Biotechnology (RGCB), Thiruvananthapuram, India).
Chemicals. Dulbecco's modified Eagle's medium was obtained from Life Technologies (Grand Island, NY, USA), antibodies against caspases, phospho-ERK1/2, phospho-JNK, phospho-p38, phospho-Akt and phospho-p65 were obtained from Cell Signaling (Beverly, MA, USA) and those against c-Jun, p65, p50, TS and PARP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 5-FU was procured from Calbiochem (San Diego, CA, USA). All other chemicals were purchased from Sigma Chemicals (St. Louis, MO, USA).
Mode of treatment. In all combination treatments, curcumin (10 mM) was added 6 h before 5-FU (10 mM) treatment. The DMSO concentration in all experiments, including controls, was p0.2%.
MTT assay. Proliferative/cytotoxic effect of 5-FU and/or curcumin was determined by MTT assay as described earlier 23 Determination of combinatorial effects. To assess whether 5-FU and curcumin act in a synergistic or additive manner with regard to cytotoxicity, the CI was determined, as proposed by Chou and Talalay. 52 Combinations having CI value o1 were taken as synergistic, those with CI value ¼ 1 were taken as additive and those with CI values 41 were taken as antagonistic. The most effective synergistic combination was selected for further studies. Western blot analysis. Total protein isolated from cells after indicated treatments were subjected to western blotting as described earlier. 23 Briefly, 60 mg of whole cell protein was resolved on a 10-15% polyacrylamide gel, transferred to a PVDF membrane, incubated with the corresponding antibody and detected by ECL (Millipore, Billerica, MA, USA).
Annexin staining. Phosphatidylserine externalization was observed by staining the cells with fluorescein isothiocyanate-conjugated Annexin V (Santa Cruz Biotechnology) according to the manufacturer's instructions and were photomicrographed. 29 Cell cycle analysis. The cell cycle analysis was conducted as reported earlier. 2 Briefly, the cells were treated with the compounds for 48 h, fixed in 70% ice-cold ethanol, treated with 100 mg/ml of RNase A and 50 mg/ml propidium iodide, and subjected to flow cytometry (BD Biosciences, San Jose, CA, USA).
Preparation of nuclear extracts and EMSA. EMSA was performed to evaluate DNA-binding activity of NF-kB or AP-1 as described earlier. 53 In brief, 10 mg of nuclear proteins was incubated for 30 min with 
